Vident Advisory LLC Purchases 1,340 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Vident Advisory LLC has increased its stake in Alnylam Pharmaceuticals by 101.0%, owning 2,667 shares worth approximately $720,000 at the end of the first quarter.
• Alnylam Pharmaceuticals reported an earnings per share (EPS) of $0.32, significantly beating analysts' estimates, and saw a revenue increase of 17.3% year-over-year, totaling $773.69 million.
• Analyst sentiment is favorable, with multiple upgrades and an average consensus price target of $417.38, reinforcing a strong "Buy" rating among 22 analysts.

Vident Advisory LLC grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 101.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,667 shares of the biopharmaceutical company's stock after acquiring an additional 1,340 shares during the quarter. Vident Advisory LLC's holdings in Alnylam Pharmaceuticals were worth $720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. SVB Wealth LLC purchased a new position in Alnylam Pharmaceuticals during the 1st quarter worth $27,000. Whipplewood Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 71 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $28,000. Finally, Colonial Trust Co SC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ:ALNY traded down $0.73 on Thursday, hitting $468.58. 1,005,288 shares of the company traded hands, compared to its average volume of 1,126,319. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a 50 day simple moving average of $398.78 and a 200-day simple moving average of $315.32. The company has a market cap of $61.42 billion, a PE ratio of -189.71 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same period last year, the company earned ($0.13) earnings per share. The company's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Colleen F. Reitan sold 18,000 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the transaction, the director directly owned 775 shares of the company's stock, valued at approximately $362,390. The trade was a 95.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the transaction, the executive vice president directly owned 50,121 shares in the company, valued at approximately $22,718,345.67. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 75,594 shares of company stock valued at $33,968,256. 1.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ALNY shares. Chardan Capital boosted their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Truist Financial started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $385.00 price objective on the stock. Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Barclays upped their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Finally, HC Wainwright reissued a "buy" rating and set a $570.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. Twenty-three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $421.28.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.